#Canada #Montreal #biotechnology #Gene Editing #DropGenie

DropGenie Secures Seed+ Financing for Advanced Gene Editing Product

In a significant advancement for the biotechnology sector, DropGenie has successfully closed its Seed+ financing round, enabling the commercialization of its groundbreaking gene editing products. This round, led by Skeleton Key, attracted additional investments from Merck Global Health Innovation Fund and CQDM, along with strong ongoing support from existing backers, Real Ventures and Anges Québec.

The newly acquired funds will support critical operations including scaling up manufacturing processes and enhancing commercial capabilities, which are essential to boost the adoption of DropGenie’s innovative technology. The funding comes on the heels of the successful validation of their platform during the Early Access Program, which has seen participation from notable global pharmaceutical and biotech firms.

DropGenie has developed a platform that facilitates high-throughput gene editing workflows, necessitating fewer cells and reagents for each experiment. This innovative approach not only reduces experimentation costs but also accelerates the editing turnaround time significantly. By allowing direct edits on primary patient cells, DropGenie's technology provides researchers with biologically relevant insights earlier in the research and development process.

Alison Hirukawa, CEO and Co-founder of DropGenie, emphasized the importance of accurate biological insights derived from direct experimentation. She stated, “The most powerful insights in biology come from perturbations—changing one thing and watching how a living system responds. But capturing those signals with fidelity demands working at the right scale, in the right cells.” Hirukawa further elaborated on how the miniaturization of workflows is set to revolutionize the research landscape.

Ann Lai, Managing Partner of Skeleton Key, has expressed strong support for DropGenie’s vision, noting, “We find the DropGenie platform's ability to reliably miniaturize and accelerate experimental workflows via automation to be extremely compelling. This is exactly the kind of science technology Skeleton Key wants to support and see succeed.”

The Seed+ financing also enhances DropGenie’s strategic partnerships aimed at generating high-quality, standardized gene editing data, responding to the growing industry demand for robust data infrastructure. Their efficient processes are designed to create the foundational datasets necessary for data-driven innovations in cell therapy and functional biology. Each dataset captured aims to reflect true biological variability, contributing to significant advancements in the field.

Headquartered in Montreal and Boston, DropGenie is poised to lead the charge in next-generation gene editing technologies. By drastically reducing the volume of cells required per experiment, the company is facilitating true biological signaling and speeding up developments in cell therapy, functional genomics, and other AI-driven discoveries.

For more insights into how DropGenie is miniaturizing gene editing workflows, you can visit their official website at DropGenie. This innovative company is clearly on a mission to redefine the future of biotechnology, making it an exciting space to watch.